Back

Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

29 June 2021 (14:00 - 15:00)
Organised by:
Congress Presentation Part of: Chronic Heart Failure - Pathophysiology and Mechanisms 1 Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Oriol Iborra Egea

Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona (Spain)

9 More presentations in this session

Presentation thumbnail
Real world analysis of outcomes of remote pulmonary artery hemodynamic monitoring in overweight and obese patients with heart failure
Doctor M. Oberoi (Sioux Falls, US)
Abstract Slides Video
Presentation thumbnail
Multicenter nationwide study of the prevalence of ATTR-CM in HFpEF in Spain. Intermediate results from national PRACTICA study.
Doctor J. Garcia-Pinilla (Malaga, ES)
Abstract Slides Video
Presentation thumbnail
HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction
Mr J. Yang (South San Francisco, US)
Abstract Slides Video
Presentation thumbnail
Pulmonary hypertension in heart failure with preserved ejection fraction: the TOPCAT Americas and PARAGON-HF studies
Doctor K. Jering (Boston, US)
Abstract Slides
Presentation thumbnail
Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF)
Doctor J. Ezekowitz (Edmonton, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic Heart Failure - Pathophysiology and Mechanisms 1

The Event

Event poster

Heart Failure 2021

29 June 2021 14:00 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitors in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis
7 April 2022
thumbnail
Congress Presentation
Artificial intelligence methods to detect heart failure with preserved ejection fraction (AIM-HFpEF) within electronic health records: an equitable disease prediction model
1 September 2025
thumbnail
Congress Presentation
GDF-15 and the effect of empagliflozin in heart failure: findings from the EMPEROR Program
20 May 2023
thumbnail
Congress Presentation
Empagliflozin improves diastolic function in obese ZSF1 rats by restoring the cardiac mitochondrial respiratory capacity.
27 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources